title: Acute hepatitis associated with treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba).
abstract: BACKGROUND
  Potassium para-aminobenzoate is an agent used in the treatment of sclerotic diseases including Peyronie's disease of the penis. It has been reported that this medication may have been responsible for cases of acute liver injury.
  
  
  OBJECTIVE
  To inform clinicians of the possibility of an adverse drug event associated with the oral intake of potassium para-aminobenzoate by reporting an additional case and compiling information from previous reports.
  
  
  METHODS
  The affected patient's medical records were diligently reviewed; all available and relevant information pertaining to this adverse event is reported. Similar case reports were analyzed and compared, and relevant information was compiled in this report.
  
  
  RESULTS
  The patient enjoyed a full biochemical recovery from his hepatitis 4 months after discontinuation of potassium para-aminobenzoate.
  
  
  CONCLUSIONS
  To date, the oral use of potassium para-aminobenzoate has been reported to be linked to acute liver injury in six individuals. Appropriate management of this adverse drug event is the immediate discontinuation of the offending drug and general patient support measures.
authors.affiliation: McGill University, Montreal, Canada. joey.roy@mail.mcgill.ca
authors.forename: Joey
authors.initials: J
authors.lastname: Roy
authors.forename: Serge
authors.initials: S
authors.lastname: Carrier
mesh_terms: D010129:4-Aminobenzoic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D000284:Administration, Oral; D000368:Aged; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D005500:Follow-Up Studies; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D010411:Penile Induration / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D010129:4-Aminobenzoic Acid